HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
医学研究院・医学院  >
雑誌発表論文等  >

Excellent Outcome of Allogeneic Hematopoietic Stem Cell Transplantation Using a Conditioning Regimen with Medium-Dose VP-16, Cyclophosphamide and Total-Body Irradiation for Adult Patients with Acute Lymphoblastic Leukemia

この資料はクリエイティブ・コモンズ・ライセンスの下で公開されています。

フルテキスト
36_1-s2.0-S1083879108001079-main.pdf253.57 kBPDF見る/開く
この文献へのリンクには次のURLを使用してください:http://hdl.handle.net/2115/62833

タイトル: Excellent Outcome of Allogeneic Hematopoietic Stem Cell Transplantation Using a Conditioning Regimen with Medium-Dose VP-16, Cyclophosphamide and Total-Body Irradiation for Adult Patients with Acute Lymphoblastic Leukemia
著者: Shigematsu, Akio 著作を一覧する
Kondo, Takeshi 著作を一覧する
Yamamoto, Satoshi 著作を一覧する
Sugita, Junichi 著作を一覧する
Onozawa, Masahiro 著作を一覧する
Kahata, Kaoru 著作を一覧する
Endo, Tomoyuki 著作を一覧する
Shiratori, Soichi 著作を一覧する
Ota, Shuichi 著作を一覧する
Obara, Masato 著作を一覧する
Wakasa, Kentaro 著作を一覧する
Takahata, Mutsumi 著作を一覧する
Takeda, Yukari 著作を一覧する
Tanaka, Junji 著作を一覧する
Hashino, Satoshi 著作を一覧する
Nishio, Mitsufumi 著作を一覧する
Koike, Takao 著作を一覧する
Asaka, Masahiro 著作を一覧する
Imamura, Masahiro 著作を一覧する
キーワード: VP-16
Acute lymphoblastic leukemia
Adult
Hematopoietic stem cell transplantation
Conditioning regimen
発行日: 2008年 5月
出版者: Elsevier
誌名: Biology of Blood and Marrow Transplantation
巻: 14
号: 5
開始ページ: 568
終了ページ: 575
出版社 DOI: 10.1016/j.bbmt.2008.02.018
抄録: We retrospectively evaluated the outcomes of 37 adult patients with acute lymphoblastic leukemia (ALL) undergoing allogeneic hematopoietic stem cell transplantation (allo-SCT) conditioned with medium-dose VP-16 (VP, 30 mg/kg), cyclophosphamide (CY, 120 mg/kg), and fractionated total-body irradiation (TBI, 12 Gy) (medium-dose VP/CY/TBI). The median age of the patients was 26 years. Thirteen patients underwent transplantation from HLA-matched related donors (MRD), 18 patients underwent transplantation from HLA-matched unrelated donors (MUD), and 6 patients underwent transplantation from HLA-mismatched donors (MMD). Thirty-two patients received bone marrow and 4 patients received peripheral blood stem cells. Ten patients were Philadelphia chromosome-positive (Ph+) and 35 patients were in complete remission (CR) at transplantation. All of the patients achieved engraftment, and grade 3 organ toxicity before engraftment occurred in 27 patients. Grade II-III acute graft-versus-host disease (GVHD) and chronic GVHD (cGVHD) occurred in 15 and 18 patients, respectively. No patient developed grade IV acute GVHD (aGVHD) or died of GVHD. At median follow-up of 35.1 months, 32 patients were alive and all Ph+ patients were alive. Three patients died of relapse and 2 died of transplant-related mortality (TRM). The actuarial 3-year overall survival (OS) rate, relapse rate, and TRM rate were 89.2%, 8.1%, and 5.4%, respectively. Non-CR at transplantation, MRD, and no aGVHD were significant adverse prognostic factors for survival. Medium-dose VP/CY/TBI for adult ALL patients was associated with lower relapse rate and no increase in toxicity, resulting in better survival.
資料タイプ: article
URI: http://hdl.handle.net/2115/62833
出現コレクション:雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

提供者: 小池 隆夫

 

本サイトに関するご意見・お問い合わせは repo at lib.hokudai.ac.jp へお願いします。 - 北海道大学